Crinetics Pharmaceuticals, Inc. (CRNX) Monday announced the appointment of Tobin Schilke as chief financial officer, effective February 28, 2025.
Schilke, with over 25 years of global pharmaceutical experience, had worked in several biotech companies, and most recently was with Revance Therapeutics as chief financial officer.
On March 10, 2025, Crinetics, a clinical stage pharmaceutical company, expects to grant Schilke 52,000 restricted stock units and a stock option to purchase 80,000 shares of common stock.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.